Skip to main content

Patient perspectives on the treatment burden of injectable medication for hereditary angioedema.

Publication ,  Journal Article
Radojicic, C; Riedl, MA; Craig, TJ; Best, JM; Rosselli, J; Hahn, R; Banerji, A
Published in: Allergy Asthma Proc
May 1, 2021

Hereditary angioedema (HAE) is a rare, chronic disease characterized by debilitating swelling episodes in various parts of the body. Patients experience significant burdens related to the symptoms and management of HAE, which can affect their daily lives and reduce their overall quality of life. Prophylactic treatment options have expanded in the past decade to the benefit of patients; however, these therapies require scheduled injections, which can be painful, burdensome, and time consuming. We conducted an online survey of patients with HAE in the USA to better understand their experiences with available prophylactic medications and the associated treatment burdens. Our survey results suggest that most patients are satisfied with their current therapies but desire novel medications with a simpler route of administration and that, although most patients experience significant treatment-related burdens, they learn to cope with these challenges over time.

Duke Scholars

Published In

Allergy Asthma Proc

DOI

EISSN

1539-6304

Publication Date

May 1, 2021

Volume

42

Issue

3

Start / End Page

S4 / S10

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Quality of Life
  • Injections
  • Humans
  • Edema
  • Angioedemas, Hereditary
  • 3204 Immunology
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Radojicic, C., Riedl, M. A., Craig, T. J., Best, J. M., Rosselli, J., Hahn, R., & Banerji, A. (2021). Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy Asthma Proc, 42(3), S4–S10. https://doi.org/10.2500/aap.2021.42.210025
Radojicic, Cristine, Marc A. Riedl, Timothy J. Craig, Jessica M. Best, Jinky Rosselli, Rebecca Hahn, and Aleena Banerji. “Patient perspectives on the treatment burden of injectable medication for hereditary angioedema.Allergy Asthma Proc 42, no. 3 (May 1, 2021): S4–10. https://doi.org/10.2500/aap.2021.42.210025.
Radojicic C, Riedl MA, Craig TJ, Best JM, Rosselli J, Hahn R, et al. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy Asthma Proc. 2021 May 1;42(3):S4–10.
Radojicic, Cristine, et al. “Patient perspectives on the treatment burden of injectable medication for hereditary angioedema.Allergy Asthma Proc, vol. 42, no. 3, May 2021, pp. S4–10. Pubmed, doi:10.2500/aap.2021.42.210025.
Radojicic C, Riedl MA, Craig TJ, Best JM, Rosselli J, Hahn R, Banerji A. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. Allergy Asthma Proc. 2021 May 1;42(3):S4–S10.

Published In

Allergy Asthma Proc

DOI

EISSN

1539-6304

Publication Date

May 1, 2021

Volume

42

Issue

3

Start / End Page

S4 / S10

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Quality of Life
  • Injections
  • Humans
  • Edema
  • Angioedemas, Hereditary
  • 3204 Immunology
  • 1107 Immunology